Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
RegulatoryapprovedTudriqevPositive
AI Analysis
Summary
Replimune received FDA approval for Tudriqev, its immunotherapy for advanced melanoma, following a 10-3 advisory committee vote in favor after two previous regulatory rejections. The approval represents a significant regulatory milestone for the company's oncology program.
Outcome Details
FDA approval for advanced melanoma immunotherapy with 10-3 advisory committee vote in favor
Importance:9/10
Sentiment:
0.95
FDA ApprovalImmunotherapyMelanomaOncologyAdvisory Committee
Related Companies
Read the original article
Published by BioSpace on August 6, 2026 8:32 PM